Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Breast 2Thoracic 1

Conditions

Breast Neoplasms 14Neoplasm Metastasis 8Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Colorectal Neoplasms 3Adenocarcinoma 3Brain Neoplasms 2Triple Negative Breast Neoplasms 1Meningeal Carcinomatosis 1HER2-mutant Non-Small Cell Lung Cancer 1Gastrointestinal Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Oxaliplatin 53Cisplatin 52Fluorouracil 50Capecitabine 48pembrolizumab 38Leucovorin 31Docetaxel 26Trastuzumab 23Paclitaxel 20Irinotecan 20Ramucirumab 12Bevacizumab 12Cetuximab 9Radiotherapy 8Surgical Procedures, Operative 7S 1 (combination) 7Nivolumab 7Epirubicin 7Carboplatin 6olaparib 5Platinum 5Everolimus 5Sunitinib 4Mitomycin 4trastuzumab deruxtecan 3lenvatinib 3epacadostat 3bemarituzumab 3apatinib 3Saline Solution 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Stomach Neoplasms × trastuzumab deruxtecan × Clear all
NCT04989816 2024-11-21

DG-06

AstraZeneca

Phase 2 Completed
95 enrolled 22 charts
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT03368196 2022-11-03

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Daiichi Sankyo

Phase 1 Completed
12 enrolled 15 charts
BreastGastrointestinal

Adenocarcinoma, Breast Neoplasms, Neoplasms, Stomach Neoplasms

NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Silverback Therapeutics

Phase 1/2 Terminated
2 enrolled 9 charts
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡